Metastatic squamous cell carcinoma of the skin with clinical response to lapatinib

Metastatic squamous cell carcinoma of the skin with clinical response to lapatinib

Abstract Background Lapatinib is a tyrosine kinase inhibitor that blocks the HER2 receptor and is typically used in the setting of metastatic breast cancer. Both ERBB2 (HER2) and ERBB3 (HER3) belong to the same family of receptor tyrosine kinases. Dimerization of these receptors leads to activation...

Full description

Bibliographic Details
Main Authors: John D. Strickley, Aaron C. Spalding, M. Tye Haeberle, Timothy Brown, Don A. Stevens, Jae Jung
Format: Article
Language:English
Published: BMC 2018-08-01
Series:Experimental Hematology & Oncology
Subjects:
Metastatic cutaneous squamous cell carcinoma
Lapatinib
ERBB3
Next generation sequencing
Online Access:http://link.springer.com/article/10.1186/s40164-018-0111-z

Internet

http://link.springer.com/article/10.1186/s40164-018-0111-z

Similar Items